

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<u>HCC-G (1 of 2)</u> External Request Submission received from GlaxoSmithKline (08/17/21): Consider adding dostarlimab-gxly as an option for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.	Based on a review of the data, the panel consensus supported including dostarlimab-gxly as a Subsequent-Line Therapy option for Hepatocellular Carcinoma if Disease Progression for patients with MSI-H/dMMR tumors. This is a category 2B, Useful in Certain Circumstances recommendation.  See Submission for references	12	7	1	11
<u>BIL-C ( 2 of 3)</u> External Request Submission from GlaxoSmithKline (08/17/21) to consider dostarlimab-gxly as an option for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment option	Based on a review of the data, the panel consensus supported including the recommendation for dostarlimab-gxly as a Subsequent-Line Therapy option for Biliary Tract Cancers if Disease Progression for patients with MSI-H/dMMR tumors. This is a category 2B, Useful in Certain Circumstances recommendation.  See Submission for references	14	5	1	11